The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?

Andrea Ghelli Luserna di Rorà 1*, Giovanni Martinelli 2 and Giorgia Simonetti 1

Abstract

Mitosis is the process whereby an eukaryotic cell divides into two identical copies. Different multiprotein complexes are involved in the fine regulation of cell division, including the mitotic promoting factor and the anaphase promoting complex. Prolonged mitosis can result in cellular division, cell death, or mitotic slippage, the latter leading to a new interphase without cellular division. Mitotic slippage is one of the causes of genomic instability and has an important therapeutic and clinical impact. It has been widely studied in solid tumors but not in hematological malignancies, in particular, in acute leukemia. We review the literature data available on mitotic regulation, alterations in mitotic proteins occurring in acute leukemia, induction of prolonged mitosis and its consequences, focusing in particular on the balance between cell death and mitotic slippage and on its therapeutic potentials. We also present the most recent preclinical and clinical data on the efficacy of second-generation mitotic drugs (CDK1-Cyclin B1, APC/CCDC20, PLK, Aurora kinase inhibitors). Despite the poor clinical activity showed by these drugs as single agents, they offer a potential therapeutic window for synthetic lethal combinations aimed to selectively target leukemic cells at the right time, thus decreasing the risk of mitotic slippage events.

Keywords: Acute leukemia, Mitotic death, Mitotic slippage, Mitotic inhibitors

Background

Stress during mitosis: cell division, death, or mitotic slippage?

Cell cycle phases in eukaryotic cells have a precise time duration that varies considerably according to cell type [1]. For example, in a highly proliferating human cell with a total doubling time of 24 h, the G1 phase may last around 11 h, S phase around 8 h, G2 around 4 h, and mitosis around 1 h [2]. Mitosis is the process whereby an eukaryotic cell divides into two identical copies. One of the most important regulators of cell division is the cyclin-dependent kinase 1 (CDK1)-Cyclin B1 complex, also known as mitotic promoting factor (MPF), which controls the progression from G2-phase to M-phase and mitosis itself [3]. CDK1 is a crucial regulator of mitotic transition and its activation drives entry into mitosis [4, 5]. MPF activity must be sustained from prophase to metaphase and subsequently turned off when cells enter anaphase. Then, MPF activity is also needed to exit mitosis [6]. MPF inactivation is obtained by the destruction of cyclin B1 through proteasome degradation and is one of the mechanisms that regulates the precise time duration of mitosis. Several studies have investigated the mechanisms underlying mitotic delay and the biological consequences of so-called “prolonged mitosis.” Different types of stimuli such as oncogene activation, DNA damages, or chromosome mis-segregation supernumerary chromosomes induce prolonged mitosis [7]. Given that mitosis is physiologically restricted to a precise time frame (minutes), prolonged mitosis (1.5–2.5 h or more) can lead to catastrophic consequences such as aneuploidy and malignant transformation [8]. However, it has been reported that in eukaryotic cells, the mitotic checkpoint can hold cells in mitosis for 12–48 h [9]. Mitotically arrested cells display mutually exclusive fates (Fig. 1a): (i) complete cell division after mitotic arrest (frequently accompanied by mis-segregation of chromosomes, thereby leading to aneuploidy); (ii) cell death in mitosis; (iii) a phenomenon known as “checkpoint adaptation”
or “mitotic slippage” in which cells return to interphase without cellular division (as tetraploid cells) [10, 11]. These cells can arrest in interphase and eventually enter cellular senescence or die after slippage [11, 23].

**Cell division after mitotic arrest**
Mitosis progression is under the control of the spindle assembly checkpoint (SAC), which selectively inhibits the anaphase promoting complex/cyclosome (APC/C) until all the kinetochores are properly attached to microtubules [24]. When the kinetochores are properly attached, the “SAC is satisfied” and SAC proteins (MAD1L1, BUB1, BUBR1, CDC20, BUB3, and MAD2L1) are released [6, 12]. Among them, CDC20, binds and activates APC/C which, in turn, polyubiquitinates structural and regulatory proteins needed for chromatid disjunction and mitosis exit, including securin and cyclin B1 [25, 26] (Fig. 1b). Securin degradation releases separase which cleaves cohesin molecules at and near sister chromatid kinetochores. As a consequence of cohesin cleavage, chromatids segregate in opposite directions at the end of anaphase [13]. Acute myeloid leukemia (AML) cell lines and primary samples display reduced BUBR1 expression compared with normal CD34+ bone marrow precursors and acute lymphoblastic leukemia (ALL) blasts [27] (Fig. 1c). Given the role of BUBR1 as an APC/C inhibitor, AML cells with reduced BUBR1 expression are able to progress through mitosis even in the presence of DNA structural aberrations, thanks to APC/C activation, which drives proteasome-dependent degradation of cyclin B1 and securin. Therefore, AML cells can skip mitotic arrest, leading to premature sister chromatid separation [27]. In addition, aberrant securin regulation, causing aneuploidy, has been reported in AML cells carrying NUP98 translocation [28] (Fig. 1c). The expression of
NUP98 fusions causes premature securin degradation in the presence of unsatisfied SAC, by interacting with APC/C\(^{Cdc20}\) and displacing BUBR1 [28, 29]. In parallel, degradation of cyclin B1 results in MPF complex inactivation and reversal of the CDK1 phosphorylation cascade by cellular phosphatases (e.g., PP1 and PP2A), which remove CDH1 inhibitory phosphorylation. Moreover, MAD2L2, which binds CDH1 during early mitosis, is degraded at anaphase, thus driving APC/C\(^{CDH1}\) activation [30, 31]. CDH1 expression is decreased in AML blasts compared with normal CD34\(^+\) cells and its downregulation was shown to inhibit cell differentiation in acute promyelocytic leukemia [32]. This evidence suggests that general mechanisms and subtype-specific alterations contribute to the aberrant regulation of cell division in acute leukemia cells.

While non-malignant cells have a remarkably limited tolerance for mitosis duration and delayed mitosis frequently ends in cell death, cancer cells tend to tolerate mitotic delay and the consequences of aberrant mitosis, such as an abnormal chromosome number [33]. Recently, mitotic errors and prolonged mitosis have been linked to chromothripsis, a form of catastrophic chromosomal rearrangement originating from one-step genomic event [34] found in leukemias [35–37] and other tumors [38]. Chromothripsis originates from genomic fragility of micronuclei containing lagging chromosomes. Micronuclei genomic instability is a consequence of nuclear envelope collapse, which occurs during interphase and hampers the capacity of sensing and repairing DNA damage [39]. It has been shown that lagging chromosomes undergo aberrant nuclear envelope assembly, with regular involvement of “core” nuclear envelope proteins, in the absence of nuclear pore complexes and other “non-core” nuclear envelope proteins [40]. The recruitment of nuclear envelope proteins is partly inhibited by Aurora B kinase through regulation of PLK1 activity, which needs to be switched off for loading of nuclear pore complexes at lagging chromosomes [41]. Moreover, a major mechanism underlying chromothripsis is represented by the inhibitory function of spindle microtubules on proper nuclear envelope assembly that in turn results in the lack of key proteins required for preserving genomic integrity in micronuclei [39, 40]. Therefore, prolonged mitosis, by disrupting spindle microtubules and mitotic exit dynamics, can trigger genomic catastrophic events.

**Cell death in mitosis**

Cell death in mitosis is an onco-suppressive mechanism that targets cells experiencing defective mitoses in order to preserve genetic integrity [42] and several molecular players are involved in its regulation (Fig. 2a and b). First, the timed degradation of the apoptosis inhibitory proteins, including BCL2, BCL-xL, and MCL1, can activate the apoptotic response and the MPF complex balances pro-apoptotic and anti-apoptotic signals. In AML cells, the exposure to microtubule poison, vinblastine, increases the amount of Cyclin B1 and the inhibitory phosphorylation of BCL-xL (Ser62), leading to the cleavage of PARP proteins and cell death [46]. Rapid induction of pro-apoptotic signals in the presence of active MPF complex also induced apoptosis during prolonged mitosis. For example, the pro-apoptotic BH3-only family member, BIM, undergoes CDK1-dependent phosphorylation in leukemia K562 cells following treatment with the microtubule targeting agents. This phosphorylation of BIM at the mitochondria correlates with mitotic arrest and precedes cell death [43]. Moreover, prolonged mitosis induced by inhibition of sphingosine kinase 1 results in CDK1-mediated inactivating phosphorylation of the pro-survival proteins BCL-2 and BCL-xL and degradation of MCL1, ultimately leading to apoptosis [44]. In addition to pro-apoptotic and anti-apoptotic protein regulation, the induction apoptosis in mitotically arrested cells has been associated with the accumulation of DNA damages during prolonged mitosis. Several studies showed that mitotic arrest is an intrinsic stimulus leading to the activation of the DNA damage response (DDR) [47, 48]. Mitotically arrested cells display a massive induction of γH2AX foci, which are markers of DNA damage sites, especially on telomeres [49]. Telomere-specific damages are enhanced by treatment with either the MCL1/BCL2/BCL-xL inhibitor, Obatoclax and is caused by the endonuclease activity of the caspase-activated DNase (CAD), which is released from its inhibitor by caspase 3 activation at telomere regions [50]. This lead to ATM and DNA-PK activation which in turn activates a P53-dependent response [8, 48]. In unperturbed cells, the tumor suppressor protein P53 is phosphorylated, stabilized, and activated during mitosis and, more precisely, during mitotic exit [51]. Activation of the P53 pathway during mitotic arrest has been extensively studied to understand how cancer cells respond to mitotic poisons (spindle or topoisomerase inhibitors). The main consequences of P53 activation are cell cycle arrest (G1 checkpoint), induction of DNA damage repair, and activation of apoptosis. Prolonged mitotic arrest induced by mitotic drugs (i.e., microtubule poisons) causes apoptosis in responsive cell lines, while cells with low sensitivity undergo slippage into tetraploid G1 cells, followed by P53-dependent arrest or apoptosis of daughter cells [48]. The events leading from prolonged mitosis to P53 activation have been organized into three hypothetical models: (i) according to the “mitotic clock” model, cells should sense the duration of mitosis and slowly accumulate P53 during mitosis [21, 52]; (ii) in the “DNA ploidy or centrosome counter checkpoint” model, P53 activation should occur in tetraploid cells after...
mitotic slippage or cytokinesis inhibition. Orth and colleagues demonstrated that P53 is not induced in apoptosis-sensitive cell lines that die during mitotic arrest, likely due to physiological inhibition of transcription and translation during mitosis [48]. However, in apoptosis-resistant cell lines, DNA damage mediates post-slipage P53 induction [50], which is induced by Aurora kinase A and B [53]. This event prevents cells from entering the cell cycle through the upregulation of the CDK inhibitor P21 [48]. We have recently showed that aneuploid AML cells have a transcriptional signature of P53 pathway inactivation, which occurs on a structural or functional base [54] and, in particular, chromothripsis [35] associates with TP53 genomic lesions. In this scenario, inactivation of p53-dependent apoptosis may result in the survival and proliferation of AML clones with complex genomic abnormalities.

Mitotic slippage
Mitotic slippage allows cell escape from death [7]. Several studies have shown that treatment failure using microtubule poisons such as taxanes (e.g., paclitaxel) and Vinca alkaloids (e.g., vinblastine and vincristine) is due to mitotic slippage in cancer cells [10, 52, 55] (Fig. 3a and b). From a mechanistic point of view, rapid degradation of Cyclin B1 and slow induction of pro-apoptotic signals (or slow degradation of pro-survival proteins) during mitotic arrest can lead to slippage (e.g., generation of polyploid cells) [56]. Evidence suggests that overexpression of the anti-apoptotic protein BCL2 can prevent death of mitotically arrested cells long enough for Cyclin B1 levels to drop below a threshold for mitotic slippage [7]. Conversely, rapid induction of pro-apoptotic signals in the presence of active MPF complex induces apoptosis during prolonged mitosis.

Fig. 2 Mechanism of cell death during mitotic arrest. a MPF complex promotes the induction of apoptosis through direct phosphorylation of different pro-/anti-apoptotic factors. CDK1-mediated inactivating phosphorylation of the BCL2 and BCL-xL and activatory phosphorylation of the pro-apoptotic BIM. MPF complex also promotes the degradation of MCL1 via APC/CCDC20. MCL1 loss promotes caspase activation leading to cell death [43–45]. b Graphic representation of the timing of reduction of Cyclin B1 level and the increment of pro-apoptotic signals in the contest of mitotic cell death. Rapid induction of pro-apoptotic signals in the presence of active MPF complex induces apoptosis during prolonged mitosis.

In AML cells, the relationship between Cyclin B1 degradation and the induction of mitotic slippage has been confirmed using Oxindole-1 (OX-1) [46]. Indeed, OX-1 treatment promotes the gradual degradation of Cyclin B1, even if the SAC is not satisfied. Cyclin B1 degradation in turn compromises the ability of MPF complex to promote apoptosis (loss of BCL-xL phosphorylation), thus generating
viable polyploid cells through mitotic slippage. This phenomenon was reversed by combining OX-1 treatment and BCL2 family inhibitors that forced AML cell apoptosis [46]. Moreover, inhibition of the CDK1 kinase activity favors mitotic slippage, polyploidy, and resistance to apoptosis in AML cells through BCL-xL stabilization, which is reversed by combined suppression of BCL-xL by ABT-263 [46]. Inhibition of Aurora B (but not Aurora A) also promotes mitotic slippage in P53-proficient cells, resulting in post-slippage P53 activation which, in turn, leads to cell cycle arrest and apoptosis [53]. In apoptosis-resistant cell lines, post-slippage P53 induction [50], which is induced by Aurora kinase A and B [53], prevents cells from entering the cell cycle through the upregulation of the CDK inhibitor P21 [48]. Despite the initial enthusiasm in Aurora kinase targeting (addressed later in the review), which was supported by their overexpression in AML cells, some concerns have been raised, due to the induction of polyploidy [57] which can occur in the absence of P53-mediated surveillance. MCL1 levels also influence slippage, with MCL1 overexpression expanding the time from mitotic entry to mitotic exit in the presence of taxol, while its inhibition leads to acceleration [56]. In this scenario, MCL1 competes with Cyclin B1 for binding to components of the proteolysis machinery, thereby slowing down the degradation of Cyclin B1 [56].

Taken together, evidence highlights the need of a timely and balanced regulation of the cell cycle machinery and the apoptotic signals during mitotic arrest, which determines the slippage versus death cellular fate. The intrinsic APC/C-mediated regulation and proteasome-dependent degradation of several pro-apoptotic and anti-apoptotic proteins play a crucial role in the fine-tuning of the cellular response and suggest that the combination of drugs targeting anti-apoptotic proteins and mitotic players can provide synergistic effects. Accordingly, it has been recently shown that the TP53 apoptotic network, and in particular inactivation of TP53, BAX, and PMAIP1, mediates resistance to BCL2 inhibition in AML [58]. A deep understanding of the precise timing of activation of mitotic players and post-translational modifications of anti-apoptotic proteins may improve the selection of the most effective combinations to kill cells during mitotic arrest, cell division, or slippage.

**Molecular alterations targeting late mitosis and its regulation in acute leukemia**

Prolonged mitosis is a common event in human cancer [59]. There is evidence that structural or functional inactivation of tumor suppressor genes can induce mitotic arrest. Inactivation of retinoblastoma (RB) through deletion or mutations, which is a
relatively rare event in both AML [60] and ALL [61–63], induces constitutive or temporary MAD2 overexpression which, in turn, delays mitosis and drives genetic instability and aneuploidy [64, 65]. Given that SAC controls progression through mitosis by regulating APC/C function and that its defective activity can lead to errors in chromosome segregation and division of cells carrying DNA damage, this surveillance mechanism is considered a major candidate for genomic alterations in human cancer, especially those exhibiting high levels of genomic instability (e.g., aneuploid tumors) [66]. However, SAC proteins are rarely mutated in solid tumors or in leukemia [54]. Conversely, SAC attenuation and deregulated expression of its components occur in several cancer types and also in acute leukemia cells (Fig. 1c). Failure of the SAC complex to sustain prolonged mitosis in response to mitotic inhibitors is responsible for the low sensitivity of AML cells to spindle poisons, which can be restored by BUBR1 or cyclin B1 induction. Compared with AML cells, lymphoblastic cell lines show higher BUBR1 expression and its knockdown reduces the accumulation of G2/M cells in response to anti-mitotic drugs [27]. Along with deregulated BUBR1, a leukemogenic MLL-fusion protein involving the mitotic regulator Blinkin (alias AF15q14) was shown to interfere with SAC activity [14]. Indeed, Blinkin participates to the recruitment of BUBR1 and BUB1 to the kinetochores and regulates their attachment to spindle microtubules, thus suggesting a causative role in genomic instability in this subgroup of MLL-driven leukemia. Moreover, AML cells expressing a C-terminally truncated form of the AML1/ETO fusion protein display attenuation leading to aberrant chromosome segregation and aneuploidy [15]. Mitotic arrest following nocodazole treatment is reduced in these cells, due to downregulation of mitotic checkpoint proteins including BUBR1 and mainly highering.

Deregulated SAC components and mitotic kinases contribute to defective mitosis in AML, with BUB1 downregulation promoting mitotic checkpoint weakening [16]. Leukemic cells also overexpress Aurora A, Aurora B, and PLK1, which induce mitotic checkpoint failure, chromosome mis-segregation, and aberrant cell cycle control, respectively [17–19]. Moreover, we and others recently showed that aneuploid and complex karyotype AML exhibits higher levels of PLK1 and CDC20 expression than euploid AML, suggesting their potential usefulness in synthetic lethal therapeutic combinations [20, 21].

The scenario is slightly different in ALL, a field in which few studies have been conducted. BUBR1, CDK1, and Aurora kinase A [22] have been shown to be upregulated in relapsed childhood B-ALL cases with respect to matched leukemic samples at diagnosis [67]. Oliveira and colleagues reported that PLK1 expression was heterogeneous in pediatric ALL cases, with no differences between the overall population and normal bone marrow cells [68]. Moreover, genes involved in spindle organization (SPC25, KIF11, ESPL1, UBE2C, TACC3), chromosome segregation (SPC25, NUSAPI, BIRC5, CCNE1, ESPL1, PTTG1), and cell division (KIF11, CCNF, NUSAPI, CCNE1, CDC20) have been found to be upregulated in pediatric B cell precursor ALL compared with normal B cell progenitors, highlighting their potential for use as therapeutic targets [69]. With regard to adult ALL cases, mRNA levels of two negative regulators of CDK1-cyclin B1 complex, WEE1 and PKMYT1, are significantly upregulated in leukemic samples with respect to normal hematopoietic precursors [70].

Preclinical and clinical data of compounds targeting mitotic stability in acute leukemia

In the last few years, several molecules have been developed that selectively target the mitotic apparatus to prevent cell duplication or enhance cell death. Here we summarize the preclinical and clinical data available in AML and ALL on the use of microtubule targeting agents (MTA) and second-generation mitotic drugs, including “mitotic blockers,” that delay mitosis progression and exit, and “mitotic drivers,” that force mitotic exit. Table 1 shows the clinical trials on targeted mitotic inhibitors used as single agents or in combination.

Conventional mitotic inhibitors

Microtubule poisons

Microtubule targeting agents (MTAs) such as vinca alkaloids, which suppress microtubule dynamics in the mitotic spindle to activate the SAC, are widely used in the clinical treatment of different types of oncohematological malignancies. Although the mechanisms of action of these drugs are only partially known, prolonged mitotic arrest appears to be a major player in the anti-proliferative activity of mitotic poisons. Vincristine (VCR), an anti-tubulin compound extracted from Catharanthus roseus, is frequently used in combination with chemotherapy for the treatment of different cancer types [100, 101]. Recently, Kothari and colleagues identified a potential mechanism of action of VCR in ALL, hypothesizing that the effect was dependent on the cell cycle phase in which the cell interacts with the anti-tubulin compound. Primary ALL cells in G1 phase were directly induced to cell death, while cells that had passed the so-called “microtubule sensitivity checkpoint” and were in late G1/early S phase continued to cycle. These cells underwent cell cycle arrest and cell death during mitosis [102]. Vinblastine is another vinca alkaloid that binds to the ends of microtubules, suppresses their dynamic
| Target          | Study                                      | Patients | Phase | Status | ClinicalTrials.gov identifier |
|-----------------|--------------------------------------------|----------|-------|--------|-------------------------------|
| CDK2, CDK5, CDK1, CDK9 | Venetoclax and dinaciclib (MK7965) | AML, relapsed/refractory | I | Recruiting | NCT03484520 |
| CDK2, CDK5, CDK1, CDK9 | Dinaciclib or gemtuzumab ozogamicin | AML/ALL, relapsed/refractory | II | Terminated | NCT00798213 [71] |
| PLK1 and other kinases | Oral rigosertib | AML, ALL, MDS, CLL, CML, relapsed/refractory | I | Completed | NCT00854646 [72] |
| PLK1 and other kinases | Rigosertib | AML, ALL, CML, relapsed/refractory, transformed MPN | I/II | Completed | NCT01167166 [73] |
| PLK1 and other kinases | Oral rigosertib | AML, MDS, relapsed/refractory or ineligible for standard chemotherapy | I/II | Completed | NCT00854945 [74] |
| PLK1 and other kinases | Oral rigosertib in combination with azacitidine | MDS, CMML, RAEB-t/non-proliferative AML | I/II | Active, not recruiting | NCT01926587 [75] |
| PLK1 | Volasertib | AML, relapsed/refractory or ineligible for standard induction therapy | I | Completed | NCT01662505 [76] |
| PLK1 | Volasertib | Pediatric leukemia, relapsed/refractory, advanced solid tumors, no available effective treatments | I | Completed | NCT01971476 [77] |
| PLK1 | BI 6727 (volasertib) as monotherapy or in combination with cytarabine | AML, relapsed/refractory or ineligible for intensive induction therapy | II | Active, not recruiting | NCT00804856 [78, 79] |
| PLK1 | Volasertib in combination with low-dose Cytarabine | Newly diagnosed AML, aged ≥ 65 years, ineligible for intensive induction therapy | III | Active, not recruiting | NCT01721876 [80] |
| PLK1 | Volasertib in combination with decitabine | AML, aged ≥ 65 years, newly diagnosed and ineligible for standard intensive therapy or relapsed/refractory | I | Terminated | NCT02003573 [81] |
| PLK1 | Intensive chemotherapy with or without volasertib | AML, newly-diagnosed, high-risk MDS | II | Terminated | NCT02198482 [82] |
| PLK1 | Onvansertib in combination with either low-dose cytarabine or decitabine | AML, relapsed/refractory or ineligible for intensive induction therapy | Ib/II | Recruiting | NCT03303339 [83] |
| PLK4 (and Aurora B) | CFI-400945 | AML, MDS, relapsed/refractory | I | Recruiting | NCT03187288 |
| Aurora A | MLN8237 | Recurrent childhood AML, ALL, solid tumors | II | Completed | NCT01154816 [84] |
| Aurora A | MLN8237 | AMKL, MF | I | Active, not recruiting | NCT02530619 [85] |
| Aurora A | MLN8237 | AML, relapsed/refractory or ineligible for intensive induction therapy, high-grade MDS | II | Completed | NCT00830518 [86] |
| Aurora A | MLN8237 in combination with 7+3 induction chemotherapy | Newly diagnosed AML | I | Completed | NCT01779843 [87] |
| Aurora A | MLN8237 with induction chemotherapy | High-risk AML, newly diagnosed | II | Active, not recruiting | NCT02560025 [88] |
| Aurora A | MLN8237 in combination with vorinostat | B/T ALL, CLL, lymphoma, relapsed/refractory | I | Completed | NCT01567709 [89] |
| Aurora B | AZD1152 | AML, relapsed/refractory or ineligible for other treatments | I | Completed | NCT00530699 [90] |
| Aurora B | AZD1152 | AML, relapsed/refractory or ineligible for other treatments | I/II | Completed | NCT00497991 [91] |
| Aurora B | AZD1152 in combination with low-dose cytosine arabinoside (LDAC) | AML, newly diagnosed, ineligible for other treatments, aged ≥ 60 | I | Completed | NCT00926731 [92] |
instability, and causes their depolymerization [103]. Different studies on leukemia and lymphoma have shown a variable response to vinblastine. One of the reported mechanisms of action of vinblastine, which correlates with sensitivity, is related to the expression of the anti-apoptotic marker MCL1. Vinblastine induces MCL1 expression via ERK1 signaling activation already after 2-h treatment in the ML-1 AML cell line [104], as a protective mechanism to acute apoptosis. Indeed, MCL1 suppression sensitized selected cell lines to vinblastine treatment. This evidence further supports the therapeutic potential of drug combinations acting on mitosis and apoptosis, and indicates that the selection of the right anti-apoptotic target (MCL2, BCL2, BCL-xL), according to the mitotic phase and patient-specific dependencies, is crucial to maximize treatment efficacy.

Microtubule-stabilizing agents (MSAs) are a second class of mitotic poisons. Among them, Paclitaxel (PTX) is the most used for the treatment of different kind of tumors. A PTX induces cell death mainly by preventing microtubule polymerization and, consequently, inducing SAC complex inhibition of cell cycle progression (arrest in G2/M phase) [105, 106]. In acute leukemia cells, the effect of PTX on the regulation of mitosis has not been investigated yet.

### Second-generation mitotic drugs

**CDK1-cyclin B1 inhibitors**

Hundreds of studies have shown the efficacy of different pan-/multi-CDK inhibitors in hematological diseases [107, 108]. Few data have been reported on the activity of Seliciclib (Roscovite), a CDK1, 2, 5, 7, 8, and 9 inhibitor, in acute leukemia. In particular, Qi and colleagues observed a dose-dependent response in AML models [108]. Conversely, there is evidence of a growth inhibitory and anti-neoplastic effect of the CDK1, 2, 5, and 9 inhibitor dinaciclib (SCH 727965) on AML and T-ALL cell lines in vitro and in vivo [44, 45]. T-ALL cells treated with dinaciclib showed decreased expression of several pro-survival proteins including survivin, cyclin

### Table 1 Clinical trials of targeted mitotic inhibitors (Continued)

| Target | Study | Patients | Phase | Status | ClinicalTrials.gov identifier |
|---|---|---|---|---|---|
| Aurora B | AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) | AML, newly diagnosed, aged ≥ 60 | II/III | Completed | NCT00952588 [90] |
| Aurora B | AZD2811 nanoparticles alone and in combination with azacitidine | AML, high-risk MDS | III | Recruiting | NCT03217838 [91] |
| Aurora A/B and other kinases | AT9283 | Acute leukemia, childhood, adult, relapsed/refractory, | I | Completed | NCT01431664 [92] |
| Aurora A/B and other kinases | AT9283 | AML, ALL, relapsed/refractory or ineligible for standard therapy, high-risk MDS, refractory CML | III | Terminated | NCT00522990 [93] |
| Aurora A/B | Orally administered AMG 900 | AML, refractory or ineligible for standard therapies | I | Completed | NCT01380756 [94] |
| Aurora A/B and other kinases | MK-0457 | CML, Ph+ ALL | I | Terminated | NCT00500006 [95] |
| Aurora A/B and other kinases | MK-0457 | T315I mutant CML, Ph + All | II | Terminated | NCT0045054 [96] |
| Aurora A/B and other kinases | MK-0457 | AML, relapsed/refractory, high-risk MDS, B-ALL, myeloproliferative diseases, CML in blast crisis | III | Completed | NCT01111683 [97] |
| Aurora A/B and other kinases | AS703569/MSC1992371A | AML, ALL, CLL, NHL, relapsed/refractory, or ineligible for standard treatment; high-risk MDS, CML, resistant or intolerant to standard treatment; myeloproliferative disorders with no effective treatment options. | I | Terminated | NCT01080664 [98] |
| Aurora A/B and other kinases | ENMD-2076 | AML, ALL, CLL, relapsed/refractory; high-risk MDS, CML | I | Completed | NCT00904787 [99] |

**ALL** acute lymphoblastic leukemia, **AMKL** acute megakaryoblastic leukemia, **AML** acute myeloid leukemia, **CLL** chronic lymphocytic leukemia, **CML** chronic myeloid leukemia, **CMML** chronic myelomonocytic leukemia, **MDS** myelodysplastic syndrome, **MF** myelofibrosis, **na** not applicable, **Ph** philadelphia chromosome

*Adult patients if not specified
Withdrawn studies were not reported*
T1, and c-MYC. The treatment also increased the number of cells in G2/M phase and induced apoptosis via the intrinsic pathway, by downregulating MCL-1 [45, 71]. In a phase II trial (NCT00798213 [71]) conducted in adult patients with advanced AML (≥60 years) or ALL, dinaciclib demonstrated anti-leukemia activity in 60% of cases. However, no objective responses were reported and MCL-1 levels rapidly recovered after drug-induced decline [71]. The drug is currently under clinical investigation in combination with the BCL2 inhibitor venetoclax (NCT03484520). The first specific CDK1 inhibitor to be developed is RO-3306, which promotes mitotic arrest in nocodazole-treated cells (G2/M arrest) [109]. RO-3306 impaired cell viability and induced apoptosis in non-small cell line, suggesting cell preparation for genome re-replication [110]. In combination with the MDM2 inhibitor Nutlin-3, RO-3306 enhanced p53-mediated BAX conformational changes and apoptosis in AML cell lines and primary cells [111]. Moreover, RO-3306 cooperated with Nutlin-3 in suppressing BCL-2, P21, and survivin expression, thus inducing apoptosis [111].

APC/C\(^{CDC20}\) inhibitors
Due to the potential tumorigenic role of CDC20 overexpression and APC/C\(^{CDC20}\) hyperactivity across cancers, several inhibitors have been tested (extensively reviewed by Wang et al. [112]). However, few studies have been conducted on acute leukemia models. Withaferin A (WA) was shown to reduce cell viability and induce apoptosis and cell cycle arrest at G2/M checkpoint in different acute leukemia cell lines [113, 114] and in primary AML cells [115]. Its anti-tumor activity is related to the inhibition of the transcription factor C/EBPβ [116]. WA was also highly effective on AF4/MLL-positive ALL cell lines, inducing cell cycle arrest, activation of the p38-downstream pathway, and DNA damage [117]. Moreover, in T-ALL cell lines, WA synergized with γ-secretase inhibitors (NOTCH inhibitor), reducing cell viability and inducing apoptosis [118].

Polo-like kinase inhibitors
Several studies have shown the efficacy of PLK1 suppression by small interfering RNA or selective PLK1 small molecule inhibitors in acute leukemia cells [119]. Among them, rigosertib and volasertib are the most widely studied in acute leukemia. Rigosertib is a non-adenosine triphosphate (ATP) competitive benzyl-styryl-sulfone analog that inhibits PLK1 and other kinases, including PI3K. In a phase I/II study on myelodysplastic syndrome (MDS) and AML patients with relapsed/refractory disease, 53% of cases demonstrated bone marrow/peripheral blood responses or stable disease, with a median survival of 15.7 and 2.0 months for responders and non-responders, respectively (NCT00854646). Volasertib (BI 6727) is an ATP-competitive kinase inhibitor that targets the ATP-binding pocket of PLK1, PLK2, and PLK3. Volasertib has proven effective as monotherapy in leukemia cell lines, primary cells, and xenograft models (especially in AML models) [119, 120], synergizing with different compounds including the proteasome inhibitor (bortezomib) [121], PI3K inhibitor [122], and bromodomain and extra-terminal motif (BET) protein inhibitor (BI 894999) [123]. In a multicenter phase I/II trial (NCT00804856), volasertib was tested as monotherapy and in combination with low-dose cytarabine in patients with relapsed/refractory AML. A higher number of patients receiving the combination obtained complete response (CR) or CR with incomplete blood count recovery (CRI), compared with those receiving cytarabine alone (31.0 vs.13.3%) [78, 79]. Following these promising results, a phase III trial was designed to test volasertib in combination with low-dose cytarabine in previously untreated elderly patients, which were ineligible for intensive chemotherapy (NCT01721876). However, the trial did not meet the primary endpoint and a negative overall survival (OS) trend was reported, due to the high frequency of fatal infections in patients receiving the drug combination [80]. An additional phase I trial of volasertib in combination with decitabine was prematurely terminated (NCT02003573), following the discontinuation of volasertib clinical development. None of the patients completed the treatment and infections were still recurrent (e.g., pneumonia reported in 46% of cases). A phase I dose-escalation study was completed in pediatric patients affected by relapsed/refractory leukemia or advanced solid tumors, with limited anti-tumor and anti-leukemia activity [77]. Recent data from our group and others, showed that PLK1 is highly expressed in aneuploid AML [20], and that complex karyotype AML, including TP53-mutated cases, is highly sensitive to volasertib, both in vitro and in vivo, in xenograft models [21]. These insights may open a new and specific therapeutic window for volasertib-based therapeutic combinations. Onvansertib (PCM-075, formerly NMS-1286937) is a highly selective, orally available, ATP-competitive inhibitor of PLK1. It causes G2/M cell cycle arrest followed by apoptosis in AML [124], ALL cell lines and primary cells from pediatric ALL expressing high PLK1 levels [125]. Moreover, it inhibited tumor growth in xenograft models from normal karyotype AML and aggressive CD56+ monoblastic AML [126], alone or in combination with cytarabine [124]. Onvansertib also synergized with FLT3 inhibitors [127]. The first results of the phase Ib/2 trial of onvansertib in combination with standard of care have been recently released, showing the greatest anti-leukemic activity in
the onvansertib+decitabine arm, with 50% of patients achieving CR (NCT03030339). Regarding PLK inhibitors, a phase I trial with CFI-400945 is currently ongoing in relapsed/refractory AML and MDS (NCT03187288). CFI-400945 was initially developed to target PLK4 that regulates centrosome duplication and genome integrity and its inhibition showed promising results in preclinical studies of solid tumors [128]. Recently, a dual activity of the drug on both PLK4 and Aurora B has been suggested [129], which may provide an intrinsic synthetic lethal combination in selected models.

**Aurora kinase inhibitors**

Several Aurora kinase inhibitors have progressed through preclinical testing and into phase I or phase II trials, including Aurora A (MLN8237, MK-5108, ENMD-2076 [130], the latter also targeting other kinases), Aurora B (AZD-1152 and AZD-2811), and a number of dual or pan-Aurora inhibitors (AST03569/MSC1992371A [131], MK-0457, AT9283, GSK1070916 [132], AMG 900 [133], PHA-739358). However, few drugs reached advanced clinical phase development in acute leukemias, due to low activity and/or intolerance of a significant patient proportion to the required dose. The efficacy of MK-5108, a selective Aurora A inhibitor, in acute leukemia, was investigated in one single study showing cytotoxic and cytostatic activity in T-ALL cell lines and primary cells [134]. The reduction in cell viability was related to a significant activation of G2/M cell cycle checkpoint followed by the induction of apoptosis. The other selective Aurora A inhibitor, MLN8237 (Alisertib), was largely studied in acute leukemia and proved in vitro efficacy, in particular on AML cells [135]. Kelly and colleagues showed that MLN8237 used as monotherapy decreased cell viability and colony-forming ability and increased apoptosis in AML models both in vitro and in vivo. The inhibitor also enhanced the cytotoxicity of cytarabine in AML cell lines and primary samples [136]. In the clinical setting, MLN8237 displayed good safety profiles when administered as single agent or in combination with chemotherapy. A phase II clinical trial reported a 13% overall response rate using MLN8237 monotherapy in relapsed/refractory AML and high-risk MDS (NCT00830518 [137]). In the same trial, 17% of AML patients obtained a partial response and 49% had a stable disease. However, a phase II trial of MLN8237 in children and adolescents with relapsed/refractory solid tumors or acute leukemia (AML and ALL) achieved an objective response rate lower than 5% [138]. Similarly, a phase I/II trial of the multi-kinase inhibitor AT9283 in children with relapsed or refractory acute leukemia carried out by Vormoor and colleagues revealed tolerable toxicity while lacking evidence of efficacy at the explored doses (NCT01431664 [92]). More promising results were obtained by MLN8237 combinatorial approaches. A phase I study (NCT01779843) of MLN8237 in combination with 7+3 induction chemotherapy in patients with AML reported an 86% remission rate (CR + CRi) [85]. Of note, 88% of patients over 65 years of age and 100% of high-risk cases (secondary acute leukemia or cytogenetically high-risk disease) obtained a composite remission. Preliminary results of the phase II trial of MLN8237 in combination with chemotherapy in high-risk patients (NCT02560025) showed a CR + CRi rate of 59% in secondary AML, 67% in patients aged ≥65, 77% in adverse risk karyotype, and of 75% TP53-mutated cases [86]. The outcome in terms of efficacy, remission rate, and survival (12% of 12-month OS, with a median follow-up of 14 months) is expected to provide positive results, which would represent a strong achievement for such a poor outcome population. The Aurora B inhibitor AZD1152 (Barasertib) has been extensively studied in acute leukemias. AZD1152 treatment reduced AML cell proliferation, induced cell death in vitro, and decreased cell growth in xenograft models [139]. These results were replicated in additional preclinical studies that showed inhibition of proliferation and induction of apoptosis in ALL and AML cells in response to Aurora B suppression by AZD1152 [57, 140, 141]. AZD1152 has also been tested in several phase I/II clinical trials, with heterogeneous effectiveness. An overall hematologic response rate of 25% was reached in newly diagnosed or relapsed AML, with manageable toxicities (NCT00497991 [88]) and in particular low neurotoxicity, which was a major issue with MTA. Forty-five percent of overall response rate resulted from a phase I study of AZD1152 with low-dose cytarabine in the elderly (NCT00926731), and a significantly improved objective CR rate was obtained in a phase II study of AZD1152 treatment compared with low-dose cytarabine in the same population (35.4% vs 11.5%, NCT00952588). AZD1152 induced responses across all cytogenetic risk groups, including those with adverse cytogenetic profiles. However, no significant improvement in OS was observed in the phase II study and AZD1152 was discontinued. Recently, Floc’h and colleagues studied the efficacy of AZD1152-hQPA (AZD2811), a nanoparticle formulation of AZD1152, in preclinical models of AML. The authors demonstrated that AZD2811 strongly inhibited tumor growth, exceeding the activity of AZD1152. The improved antitumor activity was also associated with increased phospho-histone H3 inhibition, induction of polyplody, and apoptosis [142]. AZD2811 is currently under clinical investigation as monotherapy and in combination with azacitidine (NCT03217831) and preliminary results showed a good safety profile [91]. Danusertib (PHA-739358) is a potent pan Aurora kinase inhibitor (Aurora-A IC50 = 13 nM, Aurora-B IC50 = 79 nM, Aurora-C IC50 = 61 nM) that also showed inhibitory activity against others kinases, including ABL, RET, and TRK-A. He and colleagues reported that
Danusertib negatively regulates AURKB/p70S6K/RPL15 axis with the involvement of PI3K/Akt/mTOR, AMPK, and p38 MAPK signaling pathways, leading to the induction of apoptosis and autophagy in AML cell lines [143]. Of note, danusertib inhibits both wild-type and T315I-mutant ABL kinase isoforms [144]. Danusertib efficacy was assessed in a phase I study of adult patients with CML in accelerated or blastic phase or with BCR-ABL1-positive ALL resistant or intolerant to imatinib and/or other second generation ABL kinase inhibitors. Four (20%) of the 20 evaluable patients who responded to treatment carried the T315I mutation (NCT00335868) [145].

**Future prospective: drug-to-drug synthetic lethality to target mitotic slippage**

Microtubule-binding agents, such as vinca alkaloids or taxanes, are commonly used in the clinics to treat multiple types of cancer but negative side effects, as neuro-/nefro-toxicity and drug resistance, frequently related to the need of a functional SAC for their proper activity, limit their therapeutic applicability [61]. Moreover, several cases of secondary myeloid neoplasia (MDS or AML) were reported after treatment of primary tumors with mitotic poisons such as paclitaxel. The reported cases included different solid tumors carrying a high number of cytogenetic abnormalities and with a very poor prognosis [146–149]. Besides the potential long-term side effects of the drugs, this evidence clearly points to a link between prolonged mitosis, malignant transformation, and the development of leukemia. In parallel, second-generation mitotic drugs have been developed to interfere with proper spindle formation, chromosome segregation, and/or mitotic exit, by targeting PLK1, Aurora kinases, or the APC/C. All these drugs can trigger cell death, the preferred outcome in clinical use. However, they demonstrated limited clinical success in acute leukemias, due to the unfavorable balance between dose-effectiveness and toxicity and the development of some of them has been stopped. The reported adverse effects could be prevented by reducing the inhibitor dose, thus indicating the need to develop effective combinatorial strategies, as observed in the promising combination of the Aurora A inhibitor MLN8237 with chemotherapy. The same success can be achieved by the identification of the right patients, which may benefit of a low inhibitor dose due to a high sensitivity. This approach, based on the concept of gene-to-drug synthetic lethality, has proven highly effective in cancer. Regarding mitotic inhibitors in acute leukemias, preclinical data suggest a very good response of complex karyotype AML to PLK1 inhibition [21] and of cohesion-mutated AML to disruption of APC/C CDC20 function [150]. Moreover, most mitotic inhibitors show a SAC-independent and TP53-independent activity, which represents a major breakthrough in the field, being TP53 abnormalities an absolute marker of poor prognosis. Mitotic inhibitors also favor numerical as well as structural chromosomal instability (CIN) and/or tetraploidy-mediated aneuploidy in surviving cells, which are indicative of cancer evolution, and frequently associate with chemoresistance [54]. This downside can provide a therapeutic window for synthetic lethal approaches, in which exposure to one drug greatly sensitizes to treatment with a second agent (drug-to-drug synthetic lethality). This
synthetic lethality approach has been already proven in T-ALL. Indeed, a strong synergism using volasertib in combination with MK-5108 on T-ALL cell lines [134]. A preclinical study reported synergistic inhibition of APC/C-dependent proteolysis and mitotic exit by simultaneously disrupting two protein–protein interactions within the APC/C–CDC20–substrate ternary complex using apcin and proTAME in combination [151].

**Discussion and conclusions**

Cancer cells display profound intra- and interline variation following prolonged mitosis. Mitotic slippage is a unique form of cell defense to DNA damage occurring during mitosis and is associated with genetic instability. A better understanding of this process and its molecular players would help define biomarkers that can distinguish between patients who are likely to benefit from a therapeutic regimen including mitotic inhibitors and those who may not benefit due to mitotic slippage. Shedding light on the mechanisms that orchestrate the switch from mitotic slippage to cell death is essential for an informed use of these drugs in the clinical practice. For example, P53 functionality, along with expression levels of CDK1–Cyclin B1 and anti-apoptotic proteins (MCL1, BCL2 or BCL-xL), is critical determinants of cell fate between apoptotic death and mitotic slippage. Indeed, loss of TP53 and rapid degradation of Cyclin B1 appear to promote mitotic slippage during mitotic arrest. Moreover, it has been hypothesized that mitotic slippage is promoted by the APC/C-dependent degradation of Cyclin B1 in the presence of the active mitotic checkpoint [152]. In this context, overexpression of key molecules of the APC/C may disrupt the balance between mitotic slippage and mitotic death in favor of cell survival. Leukemia-related alterations and patient-specific ones are key determinants of cell fate during mitotic arrest and of response to mitotic inhibitors.

Therefore, the introduction of second-generation mitotic inhibitors could dramatically disrupt the balance between mitotic slippage and mitotic cell death through the selection of the right patients and/or the best combination strategies to target leukemic cells. The genomic and functional characterization of leukemia will help define the therapeutic window to selectively hit cells in a precise mitotic phase, while limiting toxicity, thus facilitating the personalization of acute leukemia therapies (Fig. 4).

**Abbreviations**

ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; APC: Anaphase promoting complex/cyclosome; CDK: Cyclin-dependent kinase; CRI: Complete response; CRL: CR with incomplete blood count recovery; MDS: Myelodysplastic syndromes; MPF: Mitotic promoting factor; MTA: Microtubule targeting agents; OS: Overall survival; OX-1: Oxindole-1; SAC: Spindle assembly checkpoint; VCR: Vincristine

**Acknowledgements**

The authors wish to thank Gráinne Tienev and Cristiano Verna for editorial assistance.

**Authors’ contributions**

A.G.L.D.R and G.S. drafted the first version of the manuscript and created the figures. GM critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

**Funding**

Supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) Investigator grant, n. 19226 to Giovanni Martinelli.

**Availability of data and materials**

Not applicable

**Ethics approval and consent to participate**

Not applicable

**Consent for publication**

Not applicable

**Competing interests**

GM has competing interests with Novartis, BMS, Roche, Pfizer, ARIAD, and MSD. The other authors declare that they have no competing interests.

**Author details**

1Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, FC, Italy.

2Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, FC, Italy.

**Received:** 1 August 2019 **Accepted:** 17 October 2019

**References**

1. Araujo AR, Gelens L, Sheffin RSM, Santos SDM. Positive feedback keeps duration of mitosis temporarily insulated from upstream cell-cycle events. Mol Cell. 2016;64(2):362–75.

2. Vella F. The cell: A molecular approach. Biochem Educ. 1998;37(4):603–4.

3. Kishimoto T. Entry into mitosis: a solution to the decades-long enigma of MPF. Chromosoma. 2015;124(4):417–28.

4. Morgan DO. Cell cycle: principles of control. Yale J Biol Med. 2007;80(3):141–2.

5. Errico A, Denshmukh K, Tanaka Y, Poznakovsky A, Hunt T. Identification of substrates for cyclin dependent kinases. Adv Enzym Regul. 2010;50(1):375–99.

6. Schneec D, Yalcintepe J, Schmidt A, Becker H, Follo M, Engelhardt M, Wach W. Cell cycle control in acute myeloid leukaemia. Am J Cancer Res. 2017;2(5):508–28.

7. Haschka M, Karbon G, Fava LL, Villunger A. Perturbing mitosis for anti-cancer therapy: is cell death the only answer? EMBO Rep. 2018;19(3):1.

8. Uetake Y, Sluder G. Prolonged prometaphase blocks daughter cell proliferation despite normal completion of mitosis. Curr Biol. 2010;20(3):1666–71.

9. Brinkley BR. Mitosis in human leukemic leukocytes during colcemid inhibition and recovery. Cancer Res. 1972;32(4):746–55.

10. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell. 2008;14:111–22.

11. Cheng B, Grasta K. Consequences of mitotic slippage in antimicrotubule drug therapy. Endocr Relat Cancer. 2017;24(9):T97–T106.

12. Brown A, Geiger H. Chromosome integrity checkpoints in stem and progenitor cells: transitions upon differentiation, pathogenesis, and aging. Cell Mol Life Sci. 2018;75(20):3771–9.

13. Hornig NCD, Knowles PP, McDonald NQ, Uhlmann F. The dual mechanism of chromosome alignment and the mitotic checkpoint through direct interaction with Bub1 and BubR1. Dev Cell. 2007;13(5):663–76.

14. Kiyomitsu T, Obuse C, Yanagida M. Human Blinkin/AF15q14 is required for chromosome proteolysis and mitotic exit by simultaneously disrupting two protein–protein interactions within the APC/C–CDC20–substrate ternary complex using apcin and proTAME in combination [151].
16. Lin SF, Lin PM, Yang MC, Liu TC, Chang JG, Sue YC, Chen TP. Expression of hBUB1 in acute myeloid leukemia. Leuk Lymphoma. 2002;43:385–91.

17. Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH, Nguyen MH, Medeiros LJ, Bueso-Ramos CE. Analysis of Aurora kinase A expression in CD34+ blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop. 2009;2:2–8.

18. Lucena-Araujo AR, de Oliveira FM, Leite-Cueva SD, dos Santos GA, Falcao RP, Rego EM. High expression of AURKA and AURKB is associated with unfavourable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. Leuk Res. 2011;35:260–4.

19. Ikehara S, Yang J, Nishikawa T, Takezaki Y, Togitani K, Koellner HP, Yokoyama A. Novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia. 2009;23(9):1564–76.

20. Simonetti G, Padella A, do Valle IF, Fontana MC, Fonzi E, Bruno S, Padella A, Martinelli G. Aneuploidy: cancer driver or cancer therapist? Oncogene. 2016;35(34):4373–45.

21. Jakhar R, Luitjen MNH, Wong AFX, Cheng B, Guo K, Neo SP, Au B, Kulkarni M, Lim KJ, Maimaiti J, Dong HC, Lim EH, Tan BTB, Kong SW, Sim Y, Wong JSL, Kooi JKB, Ho JTS, Chu BT, Sinh I, Wang X, Conolly JE, Gurunathre J, Crasta KC. Polyomavirus infection promotes pro-tumorigenic effects of mitotic slippage—induced senescence. Mol Cancer Res. 2018;16(11):1625–40.

22. Suominen T, Chapi N. Checkpoint disruption in the APC/C in Hela cells is mediated by a complex of BUB1B, BUB3, CDC20, and MAD2. J Cell Biol. 2001;154(5):981–96.

23. Hershko A. Mechanisms and regulation of the degradation of cyclin B. Philos Trans R Soc B Biol Sci. 1999;354(1381):157–6.

24. Chang DC, Xu N, Luo KQ. Degradation of cyclin B is required for the onset of anaphase in mammalian cells. J Cell Biol. 2000;149(5):765–73.

25. Schnerch D, Schnirch M, Fricano J, Facchinetti A, Bernardi S, Sazinna M, Ciccarelli E, Hernandez JM, Vandenbergh P, Cools J, Bullinger L, Ottaviani E, Testoni N, Cavo M, Haffner T, et al. Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. Cancer. 2018;125:1–14.

26. Moison C, Lavalie FP, Thiellier C, Leberre H, Boivin I, Mayotte N, Gareau Y, Fréchette M, Bloquin-Chagoun V, Comeau S, Lavalie S, Lemieux S, Marinier A, Hebert J, Sauvageau G. Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition. Blood Adv. 2019;3(4):552–63.

27. Goldenson B, Crispino JD. The aurora kinases in cell cycle and leukemia. Cancers. 2019;11(10):2396.

28. Goldenson B, Crispino JD. The aurora kinases in cell cycle and leukemia. Cancers. 2019;11(10):2396.

29. Chang DC, Xu N, Luo KQ. Degradation of cyclin B is required for the onset of anaphase in mammalian cells. J Cell Biol. 2000;149(5):765–73.

30. Schnerch D, Schnirch M, Fricano J, Facchinetti A, Bernardi S, Sazinna M, Ciccarelli E, Hernandez JM, Vandenbergh P, Cools J, Bullinger L, Ottaviani E, Testoni N, Cavo M, Haffner T, et al. Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. Cancer. 2018;125:1–14.

31. Pfleger CM, Lee E, Kirschner MW. Strain recognition by the Cdc20 and Cdh1 components of the anaphase-promoting complex. Genes Dev. 2001;15(5):925.

32. Simonetti G, Padella A, do Valle IF, Fontana MC, Fonzi E, Bruno S, Padella A, Martinelli G. Aneuploidy: cancer driver or cancer therapist? Oncogene. 2016;35(34):4373–45.

33. Hershko A. Mechanisms and regulation of the degradation of cyclin B. Philos Trans R Soc B Biol Sci. 1999;354(1381):157–6.

34. Chang DC, Xu N, Luo KQ. Degradation of cyclin B is required for the onset of anaphase in mammalian cells. J Cell Biol. 2000;149(5):765–73.

35. Schnerch D, Schnirch M, Fricano J, Facchinetti A, Bernardi S, Sazinna M, Ciccarelli E, Hernandez JM, Vandenbergh P, Cools J, Bullinger L, Ottaviani E, Testoni N, Cavo M, Haffner T, et al. Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. Cancer. 2018;125:1–14.

36. Moison C, Lavalie FP, Thiellier C, Leberre H, Boivin I, Mayotte N, Gareau Y, Fréchette M, Bloquin-Chagoun V, Comeau S, Lavalie S, Lemieux S, Marinier A, Hebert J, Sauvageau G. Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition. Blood Adv. 2019;3(4):552–63.

37. Goldenson B, Crispino JD. The aurora kinases in cell cycle and leukemia. Cancers. 2019;11(10):2396.
in acute myeloid leukemia cell lines and primary patients. Haematologica. 2008;93:662–9.

58. Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones DL, D’Alessandro A, Culp-Hill R, d’Almeida A, Joshi SK, Rosenberg M, Tognoni CE, Danilov AV, Drucker BJ, Chang BH, McWeeney SK, Terney JW. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019;9(7):910–25.

59. Dalton WB, Yang VW. Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer. Future Oncol. 2009;5:1363–70.

60. Hosokawa K, Katagi T, Sugimori N, Ishiyama K, Sasaki Y, Sekii Y, Sato-Otsubo A, Sanada M, Ogasawara S, Nakao S. Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO “MDS-U” designation. Haematologica. 2012;97(2):1945–6.

61. Hofmehl F, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, Payne-Turner D, Churchmann M, Andersson A, Chen SC, Mccastill K, Beckfort J, Ma J, Wu G, Patel SN, Heatley SL, Phillips LA, Song G, Easton J, Parker M, Chen X, Rusch M, Boggis K, Vadodaria B, Hedlund E, Drenberg C, Baker S, Pei D, Cheng C, Huetter R, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45:242–52.

62. Kuper RP, Schoenmakers EFM, van Reijmersdal SV, Hehir-Kwaj JY, van Kessel AG, van Leeuwen FN, Hoogerbrugge PM. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia. 2007;21:1258–66.

63. Okamoto R, Ogasawa S, Nowak O, Kawamura N, Akagi T, Kato M, Sanada M, Weiss T, Haferlach C, Dugas M, Ruckert C, Haferlach T, Phillip-Koehler H. Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia. Haematologica. 2010;95:1481–8.

64. Herrera E, Nalhlé Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hermann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature. 2004;430(7001):792–802.

65. Chinnam M, Goodrich DW, RBl, development, and cancer. Curr Top Dev Biol. 2011;94:129–69.

66. García-Higuera I, Manchado E, Dubus P, Cañamero M, Méndez J, Moreno S, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature. 2004;430(7001):792–802.

67. Chinnam M, Goodrich DW, RBl, development, and cancer. Curr Top Dev Biol. 2011;94:129–69.

68. Garcia-Manero G, Fenaux P, Al-Kali A, Navada SC, Baer MR, Raza A, Petrone ME, Brownstein B, Patrick Si MM. LRS: comprehensive analysis of syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res. 2012;36(1):98–102.

69. Navada SC, Silverman LR, Hearn KP, Olgar K, Glass F, Pemmaraju N, Chinnam M, Goodrich DW, RBl, development, and cancer. Curr Top Dev Biol. 2011;94:129–69.

70. Kadia T, Fenaux P, Steve Fruchtman NA. GG-M: a phase II study of the combination of oral rigosertib and azacitidine in patients with myelodysplastic syndromes (MDS). Blood. 2015;126:910.

71. Kobayashi Y, Yamauchi T, Kyo H, Nakura T, Hata T, Ando K, Watabe A, Harada A, Taube T, Miyazaki Y, Naoe T. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia. Cancer Chemother Pharmacol. 2013;71(1):150–6.

72. Doo F, Locatelli F, Baruchel A, Blum N, Moeroosse B, Frappaz D, Dzworak M, Fischer M, Stary J, Fuerteg R, Rennmann K, Taube T, Reinhardt D. Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. Pediatr Blood Cancer. 2019;66(3):279–90.

73. Ottmann OG, Müller-Tidow C, Krämer A, Schlenk RF, Voss F, Taube T, Fritzsch H, Maenner J. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014;124(9):1426–33.

74. Ottmann OG, Müller-Tidow C, Krämer A, Schlenk RF, Lübbert M, Bug G, Krug U, Bochtler T, Voss F, Taube T, Liu D, Gänzler C, Dluski H. Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia. Br J Haematol. 2019;184(9):1018–21.

75. De Angelo DJ, Sekeres MA, Ottmann OG, Sanz MA, Naeim T, Taube T, Beltsack V, Ge M, Duska M, Lübbert H. Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy. Clin Lymphoma Myeloma Leuk. 2015;15:5194.

76. Amer M, Zeydan, Pamela Becker, Alexander I Spira, Prapti A, Patel, Gary J, Schiller, Michaela L, Tsi, Lara L, Lin, Maya Riding, Mark Erland SLS and JEC. Phase IIb safety, preliminary anti-leukemic activity and biomarker analysis of the polo-like kinase 1 (PLK1) inhibitor, onvisertib, in combination with low-dose cytarabine or dacarbazine in patients with relapsed or refractory acute myeloid leukemia. Clin Trials. 2019;7:913 Suppl1.

77. Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung JA, Burack R, Zhou X, Leonard EJ, Fingert H, Danabe H, Bernstein SH. Phase II study of alisertib, a selective aurora kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014;32(11):44–50.

78. Nasrampur Gargat, Brady Lee Stein, Christian Marinacco, Ronan Swords, Justin M, Watts, Sandeep Gurbuxani, Olga Frankfurt, Jessica K, Altman, Jeremy Q, Wen, Noushin Farhoud, Christopher Fauquière, Alok Patel, Roberto Tapia, Amy Handlogten, Yvonne Trang Din AT and JDC. Alisertib (MLN8237), an oral selective inhibitor of Aurora kinase a, has clinical activity and restores GATA1 expression in patients with myelofibrosis. Blood. 2018;132:6688.

79. Goldberg SL, Fenau P, Craig MD, Gyan E, Lister J, Kassis J, Pigneux A, Schiller GJ, Jung J, Jane Leonard E, Fingert H, Westervelt P. An exploratory phase 2 study of investigational Aurora a kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes. Leuk Res. 2014;38:58–61.

80. Fathi AT, Wander SA, Blonquist TM, Brunner AM, Amrein PC, Supko J, Hermance NM, Manning AL, Sadzadeh H, Ballen KK, Attar EC, Graubert TA, Hobbs G, Joseph C, Perry AM, Burke M, Silver R, Foster J, Bergeron M, Rogers AJ, Som T, Fitzsimmons KM, McGregor LR, Connolly C, Neuberg DS, Chen Y, Bin. Phase I study of the aurora a kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica. 2017, 102(4):719–727.

81. Andrew M, Brunner T, Mcllroy T, Brunner AM, Daniel J, DeAngelo, Malgorzata McMasters, Eric S, Winer, Gabriela S, Hobbs, Philip C, Amrein, Harino Hocking, David P, Steenbeek, Jacqueline S, Garcia, Marielle L, Ruskin, Richard M, Stone, Karen K, Ballen, Jacylin Rosenbl TAG and ATF: Phase II clinical trial of alisertib, an Aurora a kinase inhibitor with induction chemotherapy in high-risk, untreated patients with acute myeloid leukemia. Blood. 2018, 132:766.

82. Dennis N, Davies M, Oliver S, D’Souza R, Pike L, Stockman P. Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism, and toxicokinetics in patients with acute myeloid leukemia. Cancer Chemother Pharmacol. 2012;70:941–9.

83. Löwenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahin JY, Irfish N, Martelline G, Armorandi S, Berman E, Sonneveld P, Jongen-Lavraein M, Rigaudere S, Stockman P, Goudie A, Faderl S, Jabbour E, Kantajian H. Phase I/II study to assess the safety, efficacy, and pharmacokinetics of barasertib
103. Bates DJP, Salerni BL, Lowrey CH, Eastman A. Vinblastine sensitizes leukemia cells to cell cycle-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis. Cancer Biol Ther. 2011;12:314–25.

104. Saleni BL, Bates DJ, Albershardt TC, Lowrey CH, Eastman A. Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mc-1 is suppressed. Mol Cancer Ther. 2010;9(4):791–802.

105. He Y, Yan D, Zheng D, Hu Z, Li H, Li J. Cell division cycle 6 promotes mitotic slippage and contributes to drug resistance in paxillexil-treated cancer cells. PLoS One. 2016(11)(9):e0162633.

106. Sun RG, Chen WF, Qi H, Zhang K, Bu T, Liu Y, Wang SR. Biological effects of SWF and paxillexil on K562 human leukemia cells. Gen Pharmacol. 2012;36:11–20.

107. Bode P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs. 2013;22:723–38.

108. Qi W, Xie C, Li C, Caldwell J, Edwards H, Taub JW, Wang Y, Lin H, Ge Y. CHK1 plays a critical role in the anti-leukemic activity of the weel inhibitor MK-1775 in acute myeloid leukemia cells. J Hematol Oncol. 2014;7:53.

109. Venkatesh LJ, Tovar C, Chen S, Kreszovic D, Zhao X, Sun H, Heimbrook DC, Chen L. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci. 2006;103:10660–5.

110. Ly T, Endo A, Lamond A. Proteomic analysis of the response to cell cycle arrests in human myeloid leukemia cells. Elife. 2015;4:e05634.

111. Kojima K, Shimakau M, Shiikami M, Andreeff M, Nakamura H. Cyclin-dependent kinase 1 inhibitor Ro-3306 enhances p53-mediated Bac activation and mitochondrial apoptosis in AML. Cancer Sci. 2009;100(12):36.

112. Wang L, Zhang J, Wan L, Zhou X, Wang Z, Wei W. Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther. 2015;151:141–51.

113. Oh JH, Lee T-J, Kim SH, Choi YH, Lee SH, Lee JM, Kim Y-H; Park J-W; Kwon TK. Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation. Apoptosis. 2008;13:1494–504.

114. Okamoto S, Tsujitoka T, Suemori S, Ichino R, Ichino K, Kobayashi T, Toyohara Y, Toyama K. Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression. Cancer Sci. 2016;107:1302–1314.

115. Oben KZ, Alkhaseem SS, McKenna MK, Brandon JA, Mani R, Nootki S, Jepson L, Akunwu S, Dhar SK, Singh IP, Liang Y, Wang C, Abdel-Latif A, Stills HF, St Clair DK, Geiger H, Muthusamy N, Tohaya K, Gupta RC. Bondada S. Oxidative stress-induced JNK/AP-1 signalling is a major pathway involved in selective apoptotic of myelodysplastic syndrome cells by Withaferin-A. Oncotarget. 2017;8(44):77436–52.

116. Falkenberg KD, Jakobs A, Matern JC, Dörner W, Turk S, Hofmann E, Schernthaner KH. Withaferin A, a natural compound with anti-tumor activity, is a potent inhibitor of transcription factor C/EBPβ. Biochim Biophys Acta, Mol Cell Res. 2017;1864(7):1349–59.

117. Shi L, Wu X, Liu J, Gao Y. Withaferin A activates stress signalling proteins in high risk acute lymphoblastic leukemia. Int J Clin Exp Pathol. 2015;8:1562–3.

118. Sanchez-Martin M, Ambesi-Impiombato A, Qin Y, Herranz D, Balsal M, Girardi T, Päettn T, Eilis M, De Keersmaecker K, Caliano A, Ferrando AA. Synergistic anti-leukemic therapies in NOTCH1 -induced T-ALL. Proc Natl Acad Sci. 2017;114:2006–11.

119. Gjertsen BT, Schöffski P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia. 2014;28(1):111–9.

120. Rudolph D, Impagnatiello MA, Blaukopf C, Sommer C, Gerlich DW, Bortakour G, Garcia-Manero G, Cortes J, Kantarjian H. Epigenetic therapy is effective in elderly patients with AML. Clin Lymphoma. 2015;15(1):20–5.

121. Schnerch D, Schüler J, Follo M, Felthaus J, Wider D, Klingner K, Greil C, Duyster J, Engelhardt M, Wäsch R. Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo. Oncotarget. 2017;8(13):21153–66.

122. Adachi Y, Ishikawa Y, Kiyoi H. Identification of volasertib-resistant mechanisms and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia. Oncotarget. 2017;8(45):78492–52.

123. Tontsch-Grunt U, Rudolph D, Waizenegger I, Baum A, Gerlich DW, Bortakour G, Garcia-Manero G, Cortes J, Kantarjian H. Withaferin A suppresses the growth of Polo-like kinases, in preclinical models of acute myeloid leukemia. J Pharmacol Exp Ther 2015, 352:579–580.

124. Schnech D, Schüer J, Follo M, Feltsah J, Wider D, Klein K, Greil C, Duyster J, Engelhardt M, Wäsch R. Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo. Oncotarget. 2017;8(13):21153–66.

125. Valabusi Y, Ishikawa Y, Kiyoi H. Identification of volasertib-resistant mechanisms and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia. Oncotarget. 2017;8(45):78492–52.

126. Tontsch-Grunt U, Rudolph D, Waizenegger I, Baum A, Gerlich DW, Engelhardt H, Wurm M, Sageves F, Schweizer N, Kratn K. Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo. Cancer Lett. 2018;421:112–20.

127. Valabusi Y, Ishikawa Y, Kiyoi H. Identification of volasertib-resistant mechanisms and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia. Oncotarget. 2017;8(45):78492–52.
